Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

35.7%

5 terminated/withdrawn out of 14 trials

Success Rate

64.3%

-22.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

89%

8 of 9 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 2

2(28.6%)

7Total

N/A(5)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT05634538Not ApplicableTerminated

The ROB-OSTIAL Study

Role: lead

NCT04236856Not ApplicableCompleted

CorPath® GRX Neuro Study

Role: lead

NCT04459299Terminated

CorPath GRX STEMI Study

Role: lead

NCT04883008Terminated

NAVIGATE GRX Study

Role: lead

NCT03959072Terminated

Cardiac Cath Lab Staff Radiation Exposure

Role: lead

NCT04513613Withdrawn

ACHIEVE GRX Registry

Role: lead

NCT01917682Completed

Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions

Role: lead

NCT02742077Not ApplicableCompleted

Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease II

Role: lead

NCT03278301Completed

PRECISION GRX Registry

Role: lead

NCT03870087Completed

PRECISION GRX Post-Market Study - Japan

Role: lead

NCT03705481Not ApplicableCompleted

GRX With ReMOTE: First in Human in India

Role: lead

NCT02371785Not ApplicableCompleted

Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease

Role: lead

NCT01076036Phase 2Completed

CorPath™ 200: Robotically-Assisted Percutaneous Coronary Intervention (PCI)

Role: lead

NCT01275092Phase 2Completed

Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)

Role: lead

All 14 trials loaded